Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need-Reference-Cited by-同舟云学术

Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need

Published:2018-07-01 Issue:12 Volume:32 Page:2224-2229
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Pereira M.P.¹,Basta S.²,Moore J.³,Ständer S.¹

Affiliation:

1. Department of Dermatology and Center for Chronic Pruritus; University Hospital Münster; Münster Germany

2. Menlo Therapeutics Inc; Redwood City CA USA

3. Navigant Life Sciences; San Francisco CA USA

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.15107/fullpdf

Reference30 articles.

1. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo;Pereira;J Eur Acad Dermatol Venereol,2017

2. The pathogenesis of prurigo nodularis-’Super-Itch’ in exploration;Zeidler;Eur J Pain,2016

3. Prurigo nodularis: a benign dermatosis derived from a persistent pruritus;Vaidya;Acta Dermatovenerol Croat,2008

4. Prurigo nodularis: picking the right treatment;Saco;J Fam Pract,2015

5. Prurigo nodularis: a review;Lee;Australas J Dermatol,2005

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prurigo: review of its pathogenesis, diagnosis, and treatment;Anais Brasileiros de Dermatologia;2024-09

2. Dermatitis atópica severa en la infancia en la era de la medicina personalizada;Andes Pediatrica;2024-06-13

3. Prevalence, incidence and treatment patterns of prurigo nodularis in England: a retrospective database analysis;British Journal of Dermatology;2024-06-04

4. Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years;British Journal of Dermatology;2024-04-17

5. Validation of a scoring algorithm for the clinician‐reported outcome tool ‘prurigo activity and severity (PAS)’ based on clinical studies of dupilumab in adults with prurigo Nodularis;Journal of the European Academy of Dermatology and Venereology;2024-04-02